Drug Approval | April 02, 2024
AstraZeneca and Daiichi Sankyo’s BLA for Dato-DXd accepted in the US for treatment of breast cancer
Application based on results from the TROPION-Breast01 Phase III trial
Application based on results from the TROPION-Breast01 Phase III trial
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
For the treatment of stenotic lesions of arteriovenous fistula in the haemodialysis management of chronic renal failure
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
The surgeons were able to remove the entire breast while preserving the nipple through tiny hidden incisions
The report underscores significant advancements in healthcare delivery, showcasing how GenAI facilitates improved diagnostic accuracy, operational efficiency and patient engagement
Oscotec has successfully completed phase 2 study in patients with chronic ITP last year
New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics
The pilot plant is focused on scaling up beverage production and will support applications
Pharma Solutions operates 10 research and development and/or production sites globally
Subscribe To Our Newsletter & Stay Updated
